Dementia researchers seek solution from “inside the head”
LONDON: In their quest to find a treatment for Alzheimer’s disease, researchers at the University of Queensland are going where angels fear to tread. Driven by the idea that there’s a much better chance of treating this disease from inside the brain rather than from the outside, they are opening the hallowed blood-brain barrier and going in. This is the ultimate barrier that keeps the brain, probably the most protected organ in the body, safe.
While a thick bony skull, then a layer of fluid and then a protective membrane protect the brain from external physical injury, the blood-brain barrier, which surrounds all the blood vessels in the brain, protects it from internal injury by keeping out unwanted pathogens that travel in the blood stream; if they get in, they can cause serious inflammation and infection.
Although the UoQ researchers are not alone in the quest, their pioneering research was recognised last year as recipients of a Frontier grant from Australia’s Medical Research Future Fund.
Professor Jurgen Gotz, the team’s leader, has spent 25 years on basic research, trying to unravel the complexities of Alzheimer’s. In the past eight years he has been translating these findings into a new treatment approach. The aim is not to reverse Alzheimer’s, but to arrest the disease’s early stages.
‘‘There is a misconception about the bloodbrain barrier. In normal human and mouse brains, it is not absolutely tight. A lot of things get into the brain accidentally and it has evolved mechanisms to pump them out,’’ says Gotz, Foundation Chair of Dementia Research at the Queensland Brain Institute.
This barrier does other jobs too, letting in vitalnutrientsandmaintainingconstantlevels of water and ions in the brain. Disrupting this barrier sounds risky ‘‘and it is,’’ says Gotz.
His team has published evidence showing it can be safely done in mice and sheep. Now preparation for a human trial is underway.
The team, which includes researchers from the University of Western Australia and Sydney’s Centenary Institute, uses ultrasound and tiny injected gas bubbles to open the barrier. The ultrasound causes the bubbles to oscillate, which puts pressure on the barrier, causing it to open. This is temporary and the barrier gradually closes in the next 24 hours. The process creates a window of opportunity to clean debris out of the failing brain, much as dialysis cleans the blood when the kidneys have failed.
A brain with Alzheimer’s typically has an accumulation of plaques and tangles inhibiting its function. For unknown reasons, cells that remove this debris have become dormant. When the barrier opens, factors in the blood stream usually kept out of the brain, get in and appear to wake up the cleaners, which then resume work.
Gotz says they clean out 60 per cent to 70 per cent of the amyloid plaque in the area. Because the tangles reside inside nerve cells, smaller percentages of them are cleaned out.
This cleaning approach is different to the one pursued by drugs currently on the market for Alzheimer’s. With limited success, these drugs focus on enhancing communication between brain cells. Gotz’s team has tried different ways of penetrating the barrier in mice. Through this, it has mapped out a strategy for human trials.
‘‘First, we will use ultrasound to make the brain penetrant in a small area, and as we progress, we will systematically work through larger areas,’’ he says.
The team’s published research in mice with Alzheimer’s shows simply opening the blood–brain barrier like this improves cognition and cuts the amount of toxic, accumulated plaque. It is also exploring the benefits of transporting cargo, in the form of traditional and modern biologic drugs, through the opening, directly into the brain.
Gotz says about 98 per cent of all drugs developed for brain diseases cannot cross the barrier, posing a huge impediment to treating mental and neurological disorders.
One new drug on the Alzheimer horizon uses a monoclonal antibody (a biologic) against plaque in the brain. It’s called Aducanumab and is sponsored by Biogen. The US Food and Drug Administration has shown willingness to approve it, though only one of two final phase trials showed clinical benefits.
Gotz says one problem was that too little of the dose was getting through and being taken up. So his team cloned the antibody and, in mice, sent it into the brain with the help of ultrasound.
The results, submitted for publication, show this combination is superior to single treatment with opening the barrier alone or using the antibodies alone.
There are new frontiers in this pioneering work and the team is also exploring potential benefits of using ultrasound in aged mice without Alzheimer’s, to see if it alone improves memory and cognition.
But, of course, humans are the ultimate target, with an estimated 35 million people now living with Alzheimer’s globally and 7 million new cases diagnosed annually.
In Australia, it’s estimated up to 450,000 people have dementia, of whom 70 per cent have the most common form of it, Alzheimer’s.
Gotz says the team has also developed a prototype therapeutic ultrasound device that paves the way for a first in-human trial. One challenge has been calibrating the ultrasound dose – as the sound waves move through bone, they become attenuated.
Without opening the blood-brain barrier, other researchers have used ultrasound to treat ‘‘essential tremor’’, a neurological disorder that causes involuntary and rhythmic shaking, mostly in the hands.
They deliver ultrasound energy levels high enough to melt brain tissue that can alter the brain circuitry and stop the tremor. Gotz describes this technology as amazing.






